0001757097--12-312021Q2false6-K2021-06-30Centogene N.V.00017570972021-01-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-04-012021-06-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:EuropeMembercntg:Covid19Member2021-04-012021-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-04-012021-06-300001757097country:NLcntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097country:NLcntg:Covid19Member2021-04-012021-06-300001757097country:DEcntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097country:DEcntg:Covid19Member2021-04-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097srt:NorthAmericaMember2021-04-012021-06-300001757097srt:LatinAmericaMember2021-04-012021-06-300001757097srt:EuropeMember2021-04-012021-06-300001757097srt:AsiaPacificMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-04-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-04-012021-06-300001757097country:NL2021-04-012021-06-300001757097country:DE2021-04-012021-06-300001757097cntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:IfrsMiddleEastMember2021-04-012021-06-300001757097cntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097cntg:Covid19Member2021-04-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:Covid19Member2021-01-012021-06-300001757097srt:LatinAmericaMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:EuropeMembercntg:Covid19Member2021-01-012021-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:AsiaPacificMembercntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2021-01-012021-06-300001757097country:UScntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097country:UScntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:UScntg:Covid19Member2021-01-012021-06-300001757097country:NLcntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:NLcntg:Covid19Member2021-01-012021-06-300001757097country:DEcntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097country:DEcntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097srt:NorthAmericaMember2021-01-012021-06-300001757097srt:LatinAmericaMember2021-01-012021-06-300001757097srt:EuropeMember2021-01-012021-06-300001757097srt:AsiaPacificMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2021-01-012021-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2021-01-012021-06-300001757097country:US2021-01-012021-06-300001757097country:NL2021-01-012021-06-300001757097country:DE2021-01-012021-06-300001757097cntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:IfrsMiddleEastMember2021-01-012021-06-300001757097cntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097cntg:Covid19Member2021-01-012021-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:EuropeMembercntg:Covid19Member2020-04-012020-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-04-012020-06-300001757097country:UScntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097country:UScntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:SAcntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097country:DEcntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097country:DEcntg:Covid19Member2020-04-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097srt:NorthAmericaMember2020-04-012020-06-300001757097srt:LatinAmericaMember2020-04-012020-06-300001757097srt:EuropeMember2020-04-012020-06-300001757097srt:AsiaPacificMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-04-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-04-012020-06-300001757097country:US2020-04-012020-06-300001757097country:SA2020-04-012020-06-300001757097country:DE2020-04-012020-06-300001757097cntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:IfrsMiddleEastMember2020-04-012020-06-300001757097cntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097cntg:Covid19Member2020-04-012020-06-300001757097srt:NorthAmericaMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097srt:NorthAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:LatinAmericaMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:EuropeMembercntg:Covid19Member2020-01-012020-06-300001757097srt:AsiaPacificMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMembercntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMembercntg:Covid19Member2020-01-012020-06-300001757097country:UScntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097country:UScntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:SAcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:NLcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:DEcntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097country:DEcntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097country:DEcntg:Covid19Member2020-01-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:IfrsMiddleEastMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097srt:NorthAmericaMember2020-01-012020-06-300001757097srt:LatinAmericaMember2020-01-012020-06-300001757097srt:EuropeMember2020-01-012020-06-300001757097srt:AsiaPacificMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedOverTimeMember2020-01-012020-06-300001757097ifrs-full:PerformanceObligationsSatisfiedAtPointInTimeMember2020-01-012020-06-300001757097country:US2020-01-012020-06-300001757097country:SA2020-01-012020-06-300001757097country:NL2020-01-012020-06-300001757097country:DE2020-01-012020-06-300001757097cntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:IfrsMiddleEastMember2020-01-012020-06-300001757097cntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097cntg:Covid19Member2020-01-012020-06-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-01-012021-06-300001757097country:US2021-06-300001757097country:US2020-12-310001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerTwoMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:Covid19SegmentPartnerOneMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2020-04-012020-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:OrdinarySharesMember2021-06-300001757097ifrs-full:OrdinarySharesMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2021-01-012021-06-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:EquityShareOption2017EquitySettledMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2020-12-310001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:IfrsChiefExecutiveOfficerMember2020-12-012020-12-010001757097cntg:LpcGmbhMember2020-06-300001757097ifrs-full:CapitalReserveMember2020-01-012020-06-300001757097cntg:FollowOnEquityOfferingMembercntg:SellingShareholdersMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:FollowOnEquityOfferingMembercntg:CentogeneN.vMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:SecuredBankLoanMember2021-06-300001757097cntg:SecuredBankLoanMember2020-12-310001757097cntg:OverdraftFacilityOneMember2020-12-310001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-04-012020-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-01-012020-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:NotLaterThanOneMonthMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMemberifrs-full:CurrentMember2020-12-310001757097cntg:PartneringLaboratoryPhysicianProfDrPeterBauerMembercntg:AssociationOfStatutoryHealthInsurancePhysiciansMember2021-08-070001757097ifrs-full:RetainedEarningsMember2021-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001757097ifrs-full:NoncontrollingInterestsMember2021-06-300001757097ifrs-full:IssuedCapitalMember2021-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-06-300001757097ifrs-full:CapitalReserveMember2021-06-300001757097ifrs-full:RetainedEarningsMember2020-12-310001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001757097ifrs-full:NoncontrollingInterestsMember2020-12-310001757097ifrs-full:IssuedCapitalMember2020-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001757097ifrs-full:CapitalReserveMember2020-12-310001757097ifrs-full:RetainedEarningsMember2020-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-06-300001757097ifrs-full:NoncontrollingInterestsMember2020-06-300001757097ifrs-full:IssuedCapitalMember2020-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-06-300001757097ifrs-full:CapitalReserveMember2020-06-300001757097ifrs-full:RetainedEarningsMember2019-12-310001757097ifrs-full:NoncontrollingInterestsMember2019-12-310001757097ifrs-full:IssuedCapitalMember2019-12-310001757097ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-310001757097ifrs-full:CapitalReserveMember2019-12-310001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-04-012020-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-01-012020-06-300001757097ifrs-full:RetainedEarningsMember2021-01-012021-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001757097ifrs-full:NoncontrollingInterestsMember2021-01-012021-06-300001757097ifrs-full:IssuedCapitalMember2021-01-012021-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-06-300001757097ifrs-full:CapitalReserveMember2021-01-012021-06-300001757097ifrs-full:RetainedEarningsMember2020-01-012020-06-300001757097ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-06-300001757097ifrs-full:NoncontrollingInterestsMember2020-01-012020-06-300001757097ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-06-3000017570972020-06-3000017570972019-12-310001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2021-06-300001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2021-06-300001757097cntg:OtherBankLoansMember2021-06-300001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2020-12-310001757097ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2020-12-310001757097cntg:TradeReceivablesAndContractAssetsMember2021-06-300001757097cntg:TradeReceivablesAndContractAssetsMember2020-12-310001757097cntg:LongTermIncentivePlanMember2021-04-012021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2021-06-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2021-06-300001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-06-300001757097cntg:RostockHeadquartersBuildingMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:RostockHeadquartersBuildingMemberifrs-full:LaterThanFiveYearsMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001757097cntg:OfficeEquipmentAndStorageSpacesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:StockOptionsMember2021-01-012021-06-300001757097cntg:FollowOnEquityOfferingMemberifrs-full:OrdinarySharesMemberifrs-full:MajorPurchasesOfAssetsMember2020-07-012020-07-310001757097cntg:OverdraftFacilityMember2021-06-300001757097cntg:OverdraftFacilityMember2020-12-310001757097ifrs-full:OtherAssetsMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-06-300001757097ifrs-full:TopOfRangeMember2021-01-012021-06-300001757097ifrs-full:BottomOfRangeMember2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembersrt:ManagementMembercntg:GrantOfRestrictedStockUnitsMembercntg:LongTermIncentivePlanMembercntg:VestingInFourTranchesMember2021-07-012021-09-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMembercntg:VestingInThreeTranchesMember2021-06-300001757097cntg:StockOptionsMembercntg:LongTermIncentivePlanMember2021-06-300001757097cntg:EquityShareOption2017EquitySettledMember2021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:LongTermIncentivePlanMember2021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:PharmaceuticalPartnerMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097cntg:Covid19SegmentPartnerMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembercntg:IfrsChiefExecutiveOfficerMember2020-12-012020-12-010001757097cntg:RsuGrantedThreeMember2021-01-012021-06-300001757097cntg:LongTermIncentivePlanMember2021-01-012021-06-300001757097cntg:IfrsRestrictedStockUnitsRsusMembersrt:ManagementMembercntg:GrantOfRestrictedStockUnitsMembercntg:LongTermIncentivePlanMember2021-07-012021-09-300001757097cntg:RsuGrantedTwoMember2021-01-012021-06-300001757097cntg:RsuGrantedOneMember2021-01-012021-06-300001757097cntg:OptionsGrantedTwoMember2021-01-012021-06-300001757097cntg:OptionsGrantedOneMember2021-01-012021-06-300001757097cntg:OverdraftFacilityTwoMember2021-06-300001757097cntg:OverdraftFacilityOneMember2021-06-3000017570972020-01-012020-12-310001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2021-06-300001757097cntg:BankOverdraftsTwoMember2021-06-300001757097cntg:BankOverdraftsThreeMember2021-06-300001757097cntg:BankOverdraftsOneMember2021-06-300001757097cntg:SecuredBankLoansWithMaturityPeriod2017To22Member2020-12-310001757097cntg:BankOverdraftsTwoMember2020-12-310001757097cntg:BankOverdraftsThreeMember2020-12-310001757097cntg:BankOverdraftsOneMember2020-12-310001757097cntg:UniversitairMedischCentrumUtrechtMember2021-06-300001757097cntg:StateOfMecklenburgWesternPomeraniaMember2021-06-300001757097cntg:UniversitairMedischCentrumUtrechtMember2018-11-080001757097ifrs-full:OtherAssetsMember2021-06-300001757097ifrs-full:OtherAssetsMember2020-12-310001757097ifrs-full:LeaseLiabilitiesMember2021-06-300001757097ifrs-full:BorrowingsByNameMember2021-06-300001757097cntg:SecuredCreditLinesMember2021-06-300001757097cntg:IfrsBankOverdraftsMember2021-06-3000017570972021-06-300001757097ifrs-full:LeaseLiabilitiesMember2020-12-310001757097ifrs-full:BorrowingsByNameMember2020-12-310001757097cntg:SecuredCreditLinesMember2020-12-310001757097cntg:OtherBankLoansMember2020-12-310001757097cntg:IfrsBankOverdraftsMember2020-12-3100017570972020-12-310001757097ifrs-full:OtherAssetsMembercntg:LpcGmbhMember2021-06-300001757097cntg:LpcGmbhMember2020-01-012020-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2021-04-012021-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2021-01-012021-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-04-012020-06-300001757097ifrs-full:PropertyPlantAndEquipmentMembercountry:DEcntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:IntangibleAssetsOtherThanGoodwillMembercountry:DEcntg:Covid19Member2020-01-012020-06-300001757097ifrs-full:OtherAssetsMembercntg:RostockHeadquartersBuildingMember2021-06-300001757097ifrs-full:OtherAssetsMembercntg:BerlinOfficesMember2021-06-300001757097ifrs-full:OrdinarySharesMember2021-01-012021-06-300001757097ifrs-full:OrdinarySharesMember2020-01-012020-12-310001757097ifrs-full:OperatingSegmentsMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-04-012021-06-300001757097cntg:IfrsCorporateMember2021-04-012021-06-3000017570972021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-01-012021-06-300001757097cntg:IfrsCorporateMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-04-012020-06-300001757097cntg:IfrsCorporateMember2020-04-012020-06-3000017570972020-04-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2020-01-012020-06-300001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2020-01-012020-06-300001757097cntg:IfrsCorporateMember2020-01-012020-06-3000017570972020-01-012020-06-30cntg:Optionsiso4217:EURiso4217:CHFcntg:customerxbrli:sharescntg:trancheiso4217:EURxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the date of September 7, 2021

Commission File Number 001-39124

Centogene N.V.

(Translation of registrant’s name into English)

Am Strande 7

18055 Rostock

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F.... Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Centogene N.V.

On September 7, 2021, Centogene N.V. (the “Company”) issued a press release reporting its financial results for the six months ended June 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

Attached hereto as Exhibits 99.2 and 99.3 are also the financial statements of the Company for the three and six months ended June 30, 2021 and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2021, respectively. All exhibits attached hereto are incorporated by reference herein.

Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

Exhibits 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number 333-234551) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CENTOGENE N.V.

Date: September 7, 2021

By:

/s/ Rene Just

Name:

Rene Just

Title:

Chief Financial Officer

3

Exhibit Index

Exhibit

    

Description of Exhibit

99.1

Press Release dated September 7, 2021

99.2

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Three and Six Months ended June 30, 2021

99.3

Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months ended June 30, 2021

4

Exhibit 99.1

CENTOGENE Reports Second Quarter 2021 Financial Results

Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank


CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 7, 2021 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the second quarter ended June 30, 2021, and provided an update on recent business progress.

Executive Commentary

“We delivered a strong quarter and made meaningful progress on our strategic priorities, which we outlined at our Investor Event in June this year. This includes the appointment and onboarding of an expanded new management team, with the most recent addition of Patrice P. Denèfle as Chief Scientific Officer to help lead our data-driven approach to reinvent rare disease drug discovery and development,” stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. “By leveraging the compounding value of our leading and continuously growing Bio/Databank within our diagnostic, research, and pharma initiatives, we have built a strong foundation and are set to enable the cure of 100 rare diseases in 10 years.”

Q2 Financial Highlights

Revenues of €51.9 million in Q2 2021, a 434% increase compared to €9.7 million in Q2 2020; Revenues from the Company’s Pharma and Diagnostics segments (“Core Business”) increased 25%
Clinical Diagnostics revenues (excl. COVID) of €6.7 million, an increase of 82% compared to €3.6 million in Q2 2020
Pharma revenues of €2.8 million in Q2 2021, down from 3.9 million in Q2 2020, with further revenues weighted towards the end of 2021
Commercial COVID-19 testing revenues of €42.3 million in Q2 2021, up from €2.1 million in Q2 2020
Positive total segment adjusted EBITDA of 7.5 million compared to €1.0 million in Q2 2020 from our Pharma, Diagnostics, and COVID-19 testing segments
Cash and cash equivalents of €34.8 million as of June 30, 2021, compared to €45.2 million for the period ending March 31, 2021

“We are very encouraged by the accelerating momentum and the performance we delivered in Q2 2021, particularly in achieving strong segment adjusted EBITDA now multiple quarters in a row,” said René Just, Chief Financial Officer of CENTOGENE. “We will continue to efficiently deploy our capabilities and resources to drive further growth and value creation for our patients and shareholders.”

Corporate Highlights

Set mission to enable the cure of 100 rare diseases in 10 years and outlined high value creating strategy and milestones for the next few years at first corporate Investor Event on June 22, 2021
Published 200th scientific publication – accelerating scientific discoveries through leveraging CENTOGENE's vast Bio/Databank and studying over 115,000 patient cases to diagnose, understand, and treat rare disease patients around the world
Added approximately 24,000 patients with high quality data sets to CENTOGENE’s Bio/Databank, the world´s most geographically diverse source of rare disease-centric insights
Announced key additions to executive management team, including most recently Patrice P. Denèfle as Chief Scientific Officer, who is responsible for overseeing scientific activities to deliver on the Company’s vision and strategy, while driving value creation

Pharma Highlights

Initiated new collaboration with immuno-neurology pioneer Alector to accelerate the diagnosis of patients with frontotemporal dementia, a genetic neurogenerative disease
Extended partnership with Takeda to enable access to genetic testing and diagnosis of patients with certain genetic disorders

Extended global Parkinson’s disease study (Rostock International Parkinson's Disease (ROPAD) Study) – aiming to recruit and genetically test an additional 2,500 patients for Parkinson’s, one of CENTOGENE’s key prioritized diseases. In 2018, CENTOGENE entered into a strategic collaboration with Denali Therapeutics for the targeted global identification and recruitment of Parkinson’s disease patients with mutations in the LRRK2 gene
Currently leads 12 ongoing observational and longitudinal observational clinical studies to validate/monitor biomarkers, covering several disease categories, such as Parkinson’s disease, transthyretin amyloidosis, and inborn errors of metabolism

Diagnostic Highlights

Launched enhanced Whole Exome Sequencing (WES) service NEW CentoXome®, coupling insights from the Company’s unique rare disease-centric Bio/Databank with superior omics technology to increase diagnostic yield by up to 20% compared to conventional WES
Reported testing volume/order intake/test requests of 29,100 which represents a 54 % increase compared to 18,850 in the same period in 2020
Published latest research which led to the discovery of six new rare diseases, which are now incorporated into the Company’s diagnostic offering, and diagnosis of over 90 patients by leveraging the Company’s Bio/Databank
Authored 18 peer-reviewed scientific publications in Q2 2021, focused on generating critical insights into diseases, including Parkinson’s disease, as well as advancements in genetic sequencing technology

COVID-19 Testing

Leveraged CENTOGENE’s diagnostic expertise and resources with continued COVID-19 testing, including the processing of 679,900 test requests for SARS-CoV-2 testing in Q2 2021

2021 Financial Guidance

The Company continues to see Diagnostics recovery, alongside momentum in newly signed Pharma partnership deals. This trajectory indicates a return to solid core business growth for 2021. Despite anticipating COVID-19 revenues to decline in the second half of the year, overall revenue for FY 2021 is expected to surpass FY 2020.

Webcast and Conference Call Information

Management will host a conference call and webcast today at 2 p.m. CEST/ 8 a.m. EDT to discuss financial results and recent developments. To access the conference call and webcast, please register at: http://emea.directeventreg.com/registration/6090847. Upon registering, each participant will be provided with Participant Dial In Numbers, a Direct Event Passcode, and a unique Registrant ID. Registrants can then join up to 10 minutes prior to the start of the call.

The webcast of the conference call and the slide deck will also be available on the Investor Relations page of the Company’s website at http://investors.centogene.com.

These results reflect another step forward for CENTOGENE’s mission to enable the cure of 100 rare diseases within the next 10 years. To learn more, visit: https://www.centogene.com/virtual-investor-event

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical, genetic, and multiomic data to diagnose, understand, and treat rare diseases. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge and data. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better identification and stratification of patients and their underlying diseases to enable and accelerate discovery, development, and access to orphan drugs. As of December 31, 2020, the Company collaborated with over 30 pharmaceutical partners.


Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “continues,” “expect,” “estimate,” “intend,” “project,” and similar expressions and future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE’s business in general, see CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE’s specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Media Contact:

CENTOGENE

Lennart Streibel

Investor Relations

investor.relations@centogene.com

FTI Consulting

Robert Stanislaro

robert.stanislaro@fticonsulting.com

Rachel Kleiman

rachel.kleiman@fticonsulting.com


P30DP20DP20D

Exhibit 99.2

Centogene N.V.

Unaudited interim condensed consolidated statements of comprehensive loss

for the three and six months ended June 30, 2021 and 2020

(in EUR k)

    

    

For the three months ended June 30

    

For the six months ended June 30

Note

2020

    

2021

    

2020

    

2021

Revenue

 

4, 5

9,719

 

51,871

 

21,824

 

116,831

Cost of sales

 

6,815

 

43,760

 

13,833

 

95,707

Gross profit

 

2,904

 

8,111

 

7,991

 

21,124

Research and development expenses

 

3,119

 

4,053

 

5,810

 

8,388

General administrative expenses

 

7,767

 

10,494

 

15,665

 

22,090

Selling expenses

 

2,386

 

1,942

 

4,712

 

3,891

Impairment of financial assets

 

7

500

 

580

 

1,674

 

675

Other operating income

 

6.1

801

 

1,276

 

1,746

 

1,642

Other operating expenses

 

6.2

37

 

2

 

138

 

36

Operating loss

 

  

(10,104)

 

(7,684)

 

(18,262)

 

(12,314)

Interest and similar income

 

  

13

 

 

13

 

Interest and similar expense

 

  

269

 

212

 

718

 

471

Financial costs, net

 

(256)

 

(212)

 

(705)

 

(471)

Loss before taxes

 

  

(10,360)

 

(7,896)

 

(18,967)

 

(12,785)

Income tax expenses

 

 

124

 

129

 

124

Loss for the period

 

  

(10,360)

 

(8,020)

 

(19,096)

 

(12,909)

Other comprehensive income/ (loss), all attributable to equity holders of the parent

 

  

(6)

 

(191)

 

70

 

(70)

Total comprehensive loss

 

  

(10,366)

 

(8,211)

 

(19,026)

 

(12,979)

Attributable to:

 

  

 

 

 

Equity holders of the parent

 

  

(10,364)

 

(8,222)

 

(18,963)

 

(13,025)

Non‑controlling interests

 

  

(2)

 

11

 

(63)

 

46

(10,366)

 

(8,211)

 

(19,026)

 

(12,979)

Loss per share - Basic and diluted (in EUR)

 

  

(0.52)

 

(0.37)

 

(0.95)

 

(0.58)

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

1

Centogene N.V.

Unaudited interim condensed consolidated statements of financial position

as at December 31, 2020 and June 30, 2021

(in EUR k)

Assets

    

Note

    

Dec 31, 2020

    

June 30, 2021

Noncurrent assets

 

  

 

  

 

  

Intangible assets

 

 

12,407

 

12,179

Property, plant and equipment

 

 

16,590

 

16,411

Right-of-use assets

22,120

 

20,558

Other assets

 

7

 

1,967

 

3,023

 

53,084

 

52,171

Current assets

 

  

 

 

Inventories

 

 

11,405

 

9,281

Trade receivables and contract assets

 

7

 

29,199

 

18,490

Other assets

 

7

 

8,286

 

6,064

Cash and cash equivalents

 

8

 

48,156

 

34,780

 

97,046

 

68,615

 

150,130

 

120,786

Equity and liabilities

    

Note

    

Dec 31, 2020

    

June 30, 2021

Equity

 

  

 

  

 

  

Issued capital

 

9

 

2,654

 

2,693

Capital reserve

 

9

 

125,916

 

130,153

Retained earnings and other reserves

 

  

 

(62,888)

 

(75,913)

Non‑controlling interests

 

  

 

95

 

141

 

65,777

 

57,074

Noncurrent liabilities

 

  

 

 

Non‑current loans

 

10.1

 

401

 

200

Lease liabilities

 

10.1

 

17,677

 

16,209

Deferred tax liabilities

 

 

207

 

246

Government grants

 

10.2

 

8,950

 

8,640

 

27,235

 

25,295

Current liabilities

 

  

 

 

Government grants

 

10.2

 

1,342

 

1,352

Current loans

 

10.1

 

2,492

 

3,883

Lease liabilities

 

10.1

 

3,528

 

3,299

Trade payables

 

10.2

 

31,736

 

14,014

Liabilities from income taxes

10.2

58

143

Other liabilities

 

10.2

 

17,962

 

15,726

 

57,118

 

38,417

 

150,130

 

120,786

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

2

Centogene N.V.

Unaudited interim condensed consolidated statements of cash flows

for the six months ended June 30, 2020 and 2021

(in EUR k)

For the six months ended June 30

    

Note

    

2020

    

2021

Operating activities

 

  

 

  

 

  

Loss before taxes

 

  

 

(18,967)

(12,785)

Adjustments to reconcile loss to cash flow from operating activities

 

  

 

Amortization and depreciation

 

5

 

4,432

6,670

Interest income

 

 

(13)

Interest expense

 

 

718

471

Expected credit loss allowances on trade receivables and contract assets

7

1,674

675

Share‑based payment expenses

 

11

 

1,393

4,276

Tax expense

129

124

Other non‑cash items

 

  

 

(686)

126

Changes in operating assets and liabilities

 

  

 

Inventories

 

 

(6,252)

2,124

Trade receivables and contract assets

 

7

 

(64)

10,034

Other assets

 

7

 

269

328

Trade payables

 

10.2

 

274

(17,722)

Other liabilities

 

10.2

 

2,457

(2,151)

Cash flow used in operating activities

 

  

 

(14,636)

(7,830)

Investing activities

 

  

 

Cash paid for investments in intangible assets

 

5

 

(3,965)

(2,089)

Cash paid for investments in property, plant and equipment

 

 

(3,072)

(2,696)

Grants received for investment in property, plant and equipment

 

10.2

 

390

 

Interest received

13

Cash flow used in investing activities

 

  

 

(6,634)

(4,785)

Financing activities

 

  

 

 

Cash paid for acquisition of non-wholly owned subsidiary

(75)

Cash received from loans

 

10.1

 

928

1,769

Cash repayments of loans

 

10.1

 

(1,260)

(185)

Cash repayments of lease liabilities

 

10.1

 

(1,619)

(2,263)

Interest paid

 

 

(399)

(82)

Cash flow from used in financing activities

 

  

 

(2,425)

(761)

Changes in cash and cash equivalents

 

  

 

(23,695)

(13,376)

Cash and cash equivalents at the beginning of the period

 

  

 

41,095

48,156

Cash and cash equivalents at the end of the period

 

  

 

17,400

34,780

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

3

Centogene N.V.

Unaudited interim condensed consolidated statements of changes in equity

for the six months ended June 30, 2020 and 2021

Attributable to the owners of the parent

Currency

Non-

Issued

Capital

translation

Retained

controlling

Total

in EUR k

    

Note

    

capital

    

reserve

    

reserve

    

earnings

    

Total

    

interests

    

equity

 

As of January 1, 2020

2,383

98,099

(40,622)

59,860

(938)

58,922

Loss for the period

  

(19,033)

(19,033)

(63)

(19,096)

Other comprehensive loss

  

70

70

70

Total comprehensive loss

 

 

70

 

(19,033)

 

(18,963)

 

(63)

 

(19,026)

Share-based payments

11

1,393

1,393

1,393

Disposal of non-wholly owned subsidiary

6.2

268

268

Acquisition of non-wholly owned subsidiary

(755)

(755)

680

(75)

As of June 30, 2020

2,383

 

99,492

 

70

 

(60,410)

 

41,535

 

(53)

 

41,482

Attributable to the owners of the parent

Currency

Non-

Issued

Capital

translation

Retained

controlling

Total

in EUR k

    

Note

    

capital

    

reserve

    

reserve

    

earnings

    

Total

    

interests

    

equity

 

As of January 1, 2021

2,654

125,916

(48)

(62,840)

65,682

95

65,777

Loss for the period

  

(12,955)

(12,955)

46

(12,909)

Other comprehensive loss

  

(70)

(70)

(70)

Total comprehensive loss

 

 

(70)

 

(12,955)

 

(13,025)

 

46

 

(12,979)

Share-based payments

11

4,276

4,276

4,276

Exercise of options

39

(39)

As of June 30, 2021

2,693

 

130,153

 

(118)

 

(75,795)

 

56,933

 

141

 

57,074

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements

4

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

1General company information

Centogene N.V. (“the Company”) and its subsidiaries (“the Group”) focus on rare diseases and seek to transform real-world clinical and genetic or other data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.

On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872.

In July 2020, the Company completed a follow-on offering of 3,500,000 common shares of the Company (the “Follow-on Equity Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

2Basis of preparation

The interim condensed consolidated financial statements for the three and six months ended June 30, 2020 and 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2019 and 2020 and for the three years ended December 31, 2020. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries.

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2020. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective, and there are no new or amended standards or interpretations that are issued and became effective for the 2021 annual reporting period, that have a material impact on the Group.

These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice.

3Effect of COVID-19 Pandemic

The COVID-19 pandemic has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals.

Since the second quarter of 2020, the COVID-19 pandemic has resulted in a slowdown in our Diagnostics and Pharmaceutical businesses. As part of the Company’s initiative to assist local, national and international authorities as well as other partners in their efforts to facilitate the earliest possible diagnosis of COVID-19 and thereby contribute to allowing society to return to a “new” normal, the Company commenced testing for COVID-19 in March 2020.

5

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

During the six months ended June 30, 2021, the Group continued the COVID-19 testing activities started in 2020 with a leading role in providing testing services at airports in Germany. Furthermore, new variants of the virus have emerged since mid-December 2020. How these mutations develop and their impact on the effectiveness of vaccines is not yet fully clear. Furthermore, vaccination campaigns in several countries started during the six months ended June 30, 2021, and due to the expected increase in the availability of vaccines until the end of the year, the expectation is that governments will reduce restrictions during 2021. How and when this would affect the potential prolongation of the need for testing on a broader scale is not clear yet.

Although the Group is taking a number of measures aimed at minimizing disruptions to the business and operations, and while the provision of testing for the COVID-19 virus is anticipated to generate additional revenues for us, the full extent to which the global COVID-19 pandemic may impact the business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the pandemic, the availability of vaccines, the probability of the occurrence of further outbreaks and the ultimate impact on the financial markets and the global economy, and could result in an unforeseen negative impact on the business and future results of operations.

4Revenues from contracts with customers

in EUR k

Three Months Ended June 30, 2020(1)

    

Pharmaceutical

    

Diagnostics

    

COVID-19

Total

Rendering of services

3,606

3,684

2,053

9,343

Sales of goods

334

42

376

Total Revenues from contracts with external customers

3,940

3,684

2,095

9,719

Recognized over time

3,606

3,684

522

7,812

Recognized at a point in time

334

1,573

1,907

Total Revenues from contracts with external customers

3,940

3,684

2,095

9,719

Geographical information

Europe

 

23

1,109

 

2,095

3,227

—Germany*#

 

19

1

 

2,095

2,115

—Netherlands**

 

Middle East

 

45

1,789

 

1,834

—Saudi Arabia#

 

1,106

 

1,106

North America

 

3,872

501

 

4,373

—United States#

 

3,872

493

 

4,365

Latin America

 

219

 

219

Asia Pacific

 

66

 

66

Total Revenues from contracts with external customers

 

3,940

 

3,684

 

2,095

9,719

(1)Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the three and six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.

6

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

in EUR k

Three Months Ended June 30, 2021

    

Pharmaceutical

    

Diagnostics

COVID-19

    

Total

Rendering of services

2,653

6,715

42,325

51,693

Sales of goods

178

178

Total Revenues from contracts with external customers

2,831

6,715

42,325

51,871

Recognized over time

2,653

6,715

7,128

16,496

Recognized at a point in time

178

35,197

35,375

Total Revenues from contracts with external customers

2,831

6,715

42,325

51,871

    

Geographical information

 

Europe

 

49

1,320

42,161

43,530

—Germany*#

 

57

40,323

40,380

—Netherlands**

3

1,771

1,774

Middle East

 

26

3,950

3,976

North America

 

2,731

690

164

3,585

Latin America

 

25

608

633

Asia Pacific

 

147

147

Total Revenues from contracts with external customers

 

2,831

 

6,715

42,325

 

51,871

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#

countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended June 30, 2020 and 2021, respectively.

7

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

in EUR k

Six months ended June 30, 2020(1)

    

Pharmaceutical

    

Diagnostics

    

COVID-19

Total

Rendering of services

7,880

11,226

2,066

21,172

Sales of goods

610

42

652

Total Revenues from contracts with external customers

8,490

11,226

2,108

21,824

Recognized over time

7,880

11,226

535

19,641

Recognized at a point in time

610

1,573

2,183

Total Revenues from contracts with external customers

8,490

11,226

2,108

21,824

    

Geographical information

 

Europe

 

67

2,713

2,108

4,888

—Germany*#

 

38

61

2,108

2,207

Netherlands**

3

3

Middle East

 

48

6,204

6,252

—Saudi Arabia#

 

4,139

4,139

North America

 

8,375

1,121

9,496

—United States#

 

8,375

964

9,339

Latin America

 

965

965

Asia Pacific

 

223

223

Total Revenues from contracts with external customers

 

8,490

11,226

2,108

21,824

(1)Since the COVID-19 business has been reported as a separate segment as from the third quarter of 2020, the comparative figures for the six months ended June 30, 2020 were adjusted retrospectively for both the COVID-19 and diagnostics segments.

in EUR k

Six months ended June 30, 2021

    

Pharmaceutical

    

Diagnostics

COVID-19

Total

Rendering of services

6,046

13,098

97,302

116,446

Sales of goods

383

2

385

Total Revenues from contracts with external customers

6,429

13,098

97,304

116,831

Recognized over time

6,046

13,098

18,972

38,116

Recognized at a point in time

383

78,332

78,715

Total Revenues from contracts with external customers

6,429

13,098

97,304

116,831

    

Geographical information

 

Europe

 

198

2,534

96,282

99,014

—Germany*#

 

110

92,668

92,778

Netherlands**

5

3,539

3,544

Middle East

 

55

8,085

8,140

North America

 

6,136

1,154

944

8,234

—United States

 

6,136

1,045

944

8,125

Latin America

 

40

1,018

1,058

Asia Pacific

 

307

78

385

Total Revenues from contracts with external customers

 

6,429

13,098

97,304

116,831

*country of the incorporation of Centogene GmbH

**country of the incorporation of Centogene N.V.

#

countries contributing more than 10% of the Group’s total consolidated revenues for the six months ended June 30, 2020 and 2021, respectively.

The Group collaborated with a range of pharmaceutical partners on a worldwide basis in 2020 and 2021. In addition, in cases where pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that

8

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

the final approved treatment will be made available in several countries or globally. As a result, the Group allocates the revenues of the pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in the diagnostics segment and COVID-19 segments is based on the location of each customer.

Pharmaceutical segment

During the three and six months ended June 30, 2021, revenues from one pharmaceutical partner represented 4.1% and 4.4%, respectively, of the Group's total revenues (the three and six months ended June 30, 2020: 26.2% and 26.4%, respectively).

COVID-19 segment

During the three months ended June 30, 2021, revenues from two COVID-19 partners represented 5.2% and 12.9%, respectively, of the Group’s total revenues (the three months ended June 30, 2020: nil). In the six months ended June 30, 2021, revenues from two COVID-19 partners represented 4.7% and 15.2%, respectively, of the Group’s total revenues (the six months ended June 30, 2020: nil).

To support the COVID-19 test offerings, the Company acquired laboratory facilities and equipment, developed CENTOGENE’s Corona Test Portal and leased laboratory space at several locations in Germany. Additionally, COVID-19 testing capacity is provided through custom-built CentoTrucks, mobile laboratories in a container setup to carry out the COVID-19 analysis. Total investments in COVID-19 testing for the three and six months ended June 30, 2021 amounted to EUR 618k and EUR 2,034k, respectively, in property, plant and equipment (the three and six months ended June 30, 2020: EUR 1,873k and EUR 1,903k, respectively). An amount of EUR 354k is included in intangible assets and relates to the development of CENTOGENE’s Corona Test Portal for the six months ended June 30, 2021, no investments in intangibles were made in the three months ended June 30, 2021 (the three and six months ended June 30, 2020: EUR 527k and EUR 527k, respectively).

9

Notes to the unaudited interim condensed consolidated financial statements as of December 31, 2020 and June 30, 2021 and for the three months and six months ended June 30, 2020 and 2021

5Segment information

in EUR k

Three months ended June 30, 2020

    

Pharmaceutical

    

Diagnostics